Overview

Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Assess the effect of iontophoresis of treprostinil on wound closure over 12 weeks, in patients with DFU. In the present study the investigators aim at establishing the proof-of-concept of iontophoresis of treprostinil as a potential treatment of diabetic foot ulcers in humans. The main hypothesis is that in patients with DFUs, the pharmacodynamic effect of a PGI2 analogue potentiates the effect of low-intensity current on microvascular function, tissue oxygenation and healing.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital, Grenoble
Treatments:
Treprostinil